
Jon Mcclelland Lockard
Examiner (ID: 4263, Phone: (571)272-2717 , Office: P/1647 )
| Most Active Art Unit | 1647 |
| Art Unit(s) | 1647 |
| Total Applications | 1336 |
| Issued Applications | 815 |
| Pending Applications | 135 |
| Abandoned Applications | 414 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16776625
[patent_doc_number] => 20210113702
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-22
[patent_title] => METHODS OF TREATING AN OCULAR DISEASE OR DISORDER
[patent_app_type] => utility
[patent_app_number] => 16/985522
[patent_app_country] => US
[patent_app_date] => 2020-08-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20884
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16985522
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/985522 | Methods of treating an ocular disease or disorder | Aug 4, 2020 | Issued |
Array
(
[id] => 17838936
[patent_doc_number] => 20220276241
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-01
[patent_title] => GLYPHOSATE BIOSENSOR
[patent_app_type] => utility
[patent_app_number] => 17/628056
[patent_app_country] => US
[patent_app_date] => 2020-08-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8329
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17628056
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/628056 | GLYPHOSATE BIOSENSOR | Aug 2, 2020 | Pending |
Array
(
[id] => 16628771
[patent_doc_number] => 20210047424
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-18
[patent_title] => IMMUNOMODULATORY ANTIBODIES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/935814
[patent_app_country] => US
[patent_app_date] => 2020-07-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 63529
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16935814
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/935814 | Immunomodulatory antibodies and methods of use thereof | Jul 21, 2020 | Issued |
Array
(
[id] => 16420550
[patent_doc_number] => 20200345748
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-05
[patent_title] => METHODS FOR TREATING PAIN ASSOCIATED WITH SICKLE CELL DISEASE
[patent_app_type] => utility
[patent_app_number] => 16/934131
[patent_app_country] => US
[patent_app_date] => 2020-07-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6026
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16934131
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/934131 | Methods for treating pain associated with sickle cell disease | Jul 20, 2020 | Issued |
Array
(
[id] => 16397307
[patent_doc_number] => 20200338165
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-29
[patent_title] => THERAPEUTIC DOSING OF A NEUREGULIN OR A FRAGMENT THEREOF FOR TREATMENT OR PROPHYLAXIS OF HEART FAILURE
[patent_app_type] => utility
[patent_app_number] => 16/929218
[patent_app_country] => US
[patent_app_date] => 2020-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29493
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16929218
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/929218 | THERAPEUTIC DOSING OF A NEUREGULIN OR A FRAGMENT THEREOF FOR TREATMENT OR PROPHYLAXIS OF HEART FAILURE | Jul 14, 2020 | Abandoned |
Array
(
[id] => 16671360
[patent_doc_number] => 20210060123
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-04
[patent_title] => THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN
[patent_app_type] => utility
[patent_app_number] => 16/929379
[patent_app_country] => US
[patent_app_date] => 2020-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11498
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16929379
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/929379 | Nucleic acids encoding p75NTR neurotrophin binding proteins | Jul 14, 2020 | Issued |
Array
(
[id] => 18028955
[patent_doc_number] => 11512128
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-29
[patent_title] => VEGF/DLL4 binding agents and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/928452
[patent_app_country] => US
[patent_app_date] => 2020-07-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 14
[patent_no_of_words] => 46037
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16928452
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/928452 | VEGF/DLL4 binding agents and uses thereof | Jul 13, 2020 | Issued |
Array
(
[id] => 19519875
[patent_doc_number] => 12121573
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-10-22
[patent_title] => Methods and agents including STING agonist to treat tumor
[patent_app_type] => utility
[patent_app_number] => 16/924184
[patent_app_country] => US
[patent_app_date] => 2020-07-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 17
[patent_no_of_words] => 27188
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16924184
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/924184 | Methods and agents including STING agonist to treat tumor | Jul 8, 2020 | Issued |
Array
(
[id] => 16525291
[patent_doc_number] => 20200399371
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-24
[patent_title] => USE OF BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND MUC16 AND CD3 IN COMBINATION WITH 4-1BB CO-STIMULATION
[patent_app_type] => utility
[patent_app_number] => 16/906634
[patent_app_country] => US
[patent_app_date] => 2020-06-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26113
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16906634
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/906634 | Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation | Jun 18, 2020 | Issued |
Array
(
[id] => 17911385
[patent_doc_number] => 20220313780
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-06
[patent_title] => METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY CONDITIONS
[patent_app_type] => utility
[patent_app_number] => 17/617989
[patent_app_country] => US
[patent_app_date] => 2020-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21884
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -46
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17617989
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/617989 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY CONDITIONS | Jun 16, 2020 | Pending |
Array
(
[id] => 16391038
[patent_doc_number] => 20200331979
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-22
[patent_title] => SINGLE-CHAIN LIGHT RECEPTOR AGONIST PROTEINS
[patent_app_type] => utility
[patent_app_number] => 16/898122
[patent_app_country] => US
[patent_app_date] => 2020-06-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13615
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 111
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16898122
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/898122 | SINGLE-CHAIN LIGHT RECEPTOR AGONIST PROTEINS | Jun 9, 2020 | Abandoned |
Array
(
[id] => 16762363
[patent_doc_number] => 20210107944
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-15
[patent_title] => COMPSTATIN ANALOGS FOR TREATMENT OF NEUROPATHIC PAIN
[patent_app_type] => utility
[patent_app_number] => 16/896466
[patent_app_country] => US
[patent_app_date] => 2020-06-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16978
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16896466
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/896466 | COMPSTATIN ANALOGS FOR TREATMENT OF NEUROPATHIC PAIN | Jun 8, 2020 | Abandoned |
Array
(
[id] => 17687763
[patent_doc_number] => 20220195055
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-23
[patent_title] => ANTI-CD25 ANTIBODY AND APPLICATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/601321
[patent_app_country] => US
[patent_app_date] => 2020-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6946
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17601321
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/601321 | Anti-CD25 antibody and application thereof | Jun 7, 2020 | Issued |
Array
(
[id] => 17882744
[patent_doc_number] => 20220298221
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-22
[patent_title] => CHIMERIC AUTOANTIBODY RECEPTOR (CAAR) THAT BINDS AUTOANTIBODIES TARGETING THE CENTRAL NERVOUS SYSTEM IN NEUROLOGICAL AUTOIMMUNE DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/596145
[patent_app_country] => US
[patent_app_date] => 2020-06-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20546
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17596145
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/596145 | CHIMERIC AUTOANTIBODY RECEPTOR (CAAR) THAT BINDS AUTOANTIBODIES TARGETING THE CENTRAL NERVOUS SYSTEM IN NEUROLOGICAL AUTOIMMUNE DISEASE | Jun 4, 2020 | Pending |
Array
(
[id] => 16776584
[patent_doc_number] => 20210113661
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-22
[patent_title] => FORMULA OF NEUREGULIN PREPARATION
[patent_app_type] => utility
[patent_app_number] => 16/894540
[patent_app_country] => US
[patent_app_date] => 2020-06-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11842
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16894540
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/894540 | Formula of neuregulin preparation | Jun 4, 2020 | Issued |
Array
(
[id] => 19923008
[patent_doc_number] => 12297279
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-13
[patent_title] => Compositions and methods for treating pain in subjects with rheumatoid arthritis
[patent_app_type] => utility
[patent_app_number] => 16/891984
[patent_app_country] => US
[patent_app_date] => 2020-06-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 4
[patent_no_of_words] => 6594
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 186
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16891984
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/891984 | Compositions and methods for treating pain in subjects with rheumatoid arthritis | Jun 2, 2020 | Issued |
Array
(
[id] => 17734726
[patent_doc_number] => 20220220185
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-14
[patent_title] => METHOD AND SYSTEM FOR PREDICTING COUPLING PROBABILITIES OF G-PROTEIN COUPLED RECEPTORS WITH G-PROTEINS
[patent_app_type] => utility
[patent_app_number] => 17/615000
[patent_app_country] => US
[patent_app_date] => 2020-05-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26439
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -1
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17615000
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/615000 | METHOD AND SYSTEM FOR PREDICTING COUPLING PROBABILITIES OF G-PROTEIN COUPLED RECEPTORS WITH G-PROTEINS | May 28, 2020 | Pending |
Array
(
[id] => 17776607
[patent_doc_number] => 20220242956
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-04
[patent_title] => ACTRII-BINDING PROTEINS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/615474
[patent_app_country] => US
[patent_app_date] => 2020-05-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43586
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17615474
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/615474 | ACTRII-BINDING PROTEINS AND USES THEREOF | May 28, 2020 | Pending |
Array
(
[id] => 16353136
[patent_doc_number] => 10793637
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-10-06
[patent_title] => Antibodies that bind CD39 and uses thereof
[patent_app_type] => utility
[patent_app_number] => 15/931469
[patent_app_country] => US
[patent_app_date] => 2020-05-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 19
[patent_no_of_words] => 59119
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 79
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15931469
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/931469 | Antibodies that bind CD39 and uses thereof | May 12, 2020 | Issued |
Array
(
[id] => 16483965
[patent_doc_number] => 20200377566
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-03
[patent_title] => MODIFIED LIGAND-GATED ION CHANNELS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 16/868205
[patent_app_country] => US
[patent_app_date] => 2020-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18569
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16868205
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/868205 | Modified ligand-gated ion channels and methods of use | May 5, 2020 | Issued |